ClinicalTrials.gg
Active, not recruitingNCT04740424Updated Nov 4, 2026

FS222 First in Human Study in Patients With Advanced Malignancies

A Phase 1 interventional study of FS222 in Advanced Cancer and Metastatic Cancer, sponsored by invoX Pharma Limited. Active, not recruiting at 21 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by invoX Pharma Limited (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Updated Nov 4, 2026Now Active, not recruiting2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 414 studies in Neoplasm Metastasis with a site in Spain — 78 open to participants now, 143 under way, 43 of them phase 3. Neoplasm Metastasis · Spain.

Planned enrollment
151st of 392
260 · median 165
Started
2020
with 23 others
Phase 1
94 of 414
15 open now
Primary completion
2027-10
later than 81 of 142 live
Registered
265th of 414
by date

Among the 414 studies in Neoplasm Metastasis with a site in Spain, this one is the 151st largest by planned enrollment of the 392 interventional ones that give a count, is one of 24 that started in 2020, is one of 94 in phase 1, reaches primary completion later than 81 of the 142 other live ones, and was the 265th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

78 of the 414 studies in Neoplasm Metastasis with a site in Spain are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 414 studies in Neoplasm Metastasis with a site in Spain, or all of them as a file.
02

Study summary

This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer

Browse trials for

Keywords

  • Immuno-oncology
  • bispecific antibody
  • dose escalation
  • cohort expansion
  • CD137
  • PD-L1
  • F-star
  • 4-1BB
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Participants with or cytologically confirmed, locally advanced, unresectable or solid tumours for whom standard therapy has proven to be ineffective, intolerable or is considered inappropriate. This criterion does not apply to the PK/PD expansion cohort, where tumour-specific criteria will apply instead.
  • No more than 1 with ICB treatment. Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
  • Participants who have received prior ICB, or any concurrent chemotherapy, radiotherapy, , biologic or hormonal therapy for cancer treatment may be eligible for enrolment following a .
  • Participants who have received prior therapy are eligible if PD-L1 therapy was discontinued ≥6 months prior to entry into the study.
  • Participants who have failed a prior ICB regimen should document it.
  • . Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
  • Performance Status ≤1.
  • The participant agrees to undergo a mandatory pre-treatment and on-treatment of the tumour. Certain exceptions apply.
  • Highly effective .
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Participants with COVID-19 disease risk will be excluded from enrolment during the COVID-19 pandemic.
  • Concurrent enrolment in another clinical study with the exception of non-interventional/observational studies or the follow-up period of an interventional study.
  • Prior treatment with CD137 agonist mAb or other experimental agonists.
  • For participants who have received prior ICB, participants must not have received more than 1 with ICB(s). Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
  • Participants with active disease.
  • Receipt of any within 30 days prior to the first dose of study drug.
  • Receipt of a live attenuated vaccine within 30 days prior to the first dose of study drug.
  • History of uncontrolled intercurrent illness.
  • Psychological, familial, sociological or geographical conditions that do not permit compliance with the protocol.
  • Judgment by the investigator that the participant is unsuitable to participate in the study, and the participant is unlikely to comply with study procedures, restrictions and requirements.
  • Significant laboratory abnormalities.
  • Known infections.
  • Uncontrolled , primary CNS tumours with CNS metastases as only . Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
  • Prior history of any Grade ≥3 irAE that has not improved to Grade ≤1, except for endocrine deficiencies that are managed by HRT; significant treatment-related cytokine release syndrome; systemic inflammatory response syndrome.
  • Current use of agents, prior organ transplantation requiring immunosuppression, or intolerance to mAb or their , or persisting toxicity related to prior therapy of Grade >1 Version 5.0 .
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    FS222 Q4W

    The initial cohorts will enroll sequentially as single participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design. Additional participants will be recruited into the PK/PD expansion cohorts at dose levels deemed safe during dose escalation. Once a tolerated dose has been established participants will be recruited into tumour-specific expansion cohorts.

    Drug: FS222

Interventions

  • DrugFS222

    Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.

06

What researchers measure

Primary outcomes

  1. Presence of adverse events (AEs) and serious adverse events (SAEs)

    Safety and tolerability will be evaluated by collection of AEs and SAEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

    Time frame: 15 months

  2. Determination of a maximum tolerated dose (MTD) by evaluation of DLTs

    Toxicity will be evaluated according to the NCI CTCAE Version 5.0.

    Time frame: 28 days

  3. Determination of a recommended Phase 2 dose (RP2D) by evaluation of DLTs

    Toxicity will be evaluated according to the NCI CTCAE Version 5.0.

    Time frame: 28 days

07

Study locations

21 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Oct 2027, 82 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 82 months is above that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 5, 2021
StartActual
Dec 14, 2020
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Spain)
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital Clinico Universitario de Valencia · Valencia, Spain
Show 2 removed
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital Clinico Universitario de Valencia · Valencia, Spain
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    2 sites added, 2 sites removed
    Show 2 added (2 Spain)
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital Clinico Universitario de Valencia · Valencia, Spain
    Show 2 removed
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital Clinico Universitario de Valencia · Valencia, Spain
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04740424
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Dec 14, 2020
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Nov 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion